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Objective: HIV genotype-resistance testing can help identify
more effective antiretroviral treatment (ART) regimens for pa-
tients, substantially increasing the likelihood of viral suppression
and immune recovery. We sought to evaluate the cost-
effectiveness of genotype-resistance testing before ﬁrst-line ART
initiation in Brazil.
Design: We used a previously published microsimulation model
of HIV disease (CEPAC-International) and data from Brazil to
compare the clinical impact, costs, and cost-effectiveness of
initial genotype testing (Genotype) with no initial genotype
testing (No genotype).
Methods: Model parameters were derived from the HIV Clinical
Cohort at the Evandro Chagas Clinical Research Institute and from
published data, using Brazilian sources whenever possible.
Baseline patient characteristics included 69% male, mean age of
36 years (SD, 10 years), mean CD4 count of 347 per microliter
(SD, 300/mL) at ART initiation, annual ART costs from 2012 US
$1400 to US $13,400, genotype test cost of US $230, and primary
resistance prevalence of 4.4%. Life expectancy and costs were
discounted 3% per year. Genotype was deﬁned as “cost-effective”
compared with No Genotype if its incremental cost-effectiveness
ratio was less than 3 times the 2012 Brazilian per capita GDP of
US $12,300.
Results: Compared with No genotype, Genotype increased life
expectancy from 18.45 to 18.47 years and reduced lifetime cost
from US $45,000 to $44,770; thus, in the base case, Genotype
was cost saving. Genotype was cost-effective at primary resis-
tance prevalence as low as 1.4% and remained cost-effective
when subsequent-line ART costs decreased to 30% of baseline
value. Cost-inefﬁcient results were observed only when simulta-
neously holding multiple parameters to extremes of their
plausible ranges.
Conclusions: Genotype-resistance testing in ART-naive individu-
als in Brazil will improve survival and decrease costs and should be
incorporated into HIV treatment guidelines in Brazil.
Key Words: genotype, cost-effectiveness, Brazil, HIV, drug resistance
(J Acquir Immune Deﬁc Syndr 2015;68:152–161)
INTRODUCTION
The Brazilian Ministry of Health’s response to the HIV/
AIDS epidemic is recognized worldwide as a bold program
for a middle-income country.
1–3 One of the most striking
characteristics of the program is the universal provision of
antiretroviral treatment (ART) free of charge to patients,
which was guaranteed in 1996 through the passage of a federal
law.
4 At the same time, an expert panel was designated to
deﬁne guidelines for the treatment of infected individuals in
the country. Noteworthy aspects of the most recent guide-
lines, issued in 2013, include CD4 count threshold for
treatment initiation at ,500 per microliter, regular use of
CD4 count and HIV RNA quantiﬁcation assays for treatment
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salvage therapy, and use of genotype-resistance testing after
treatment failure.
5
One notable omission concerns the use of genotype-
resistance testing before ART initiation for ART-naive
patients. The guidelines exclude the widespread use of
genotype-resistance testing for ART-naive patients, which is
only recommended for pregnant women or individuals known
to have acquired infection from a partner receiving ART. This
omission is noteworthy, given that the epidemiology and
economics of HIV have been shown to favor the use of
genotype-resistance testing not only after failing an ART
regimen in resource-rich
6,7 and resource-limited settings,
8 but
also for patients who are ART naive in resource-rich settings.
9
By identifying individuals with primary resistance, genotype
resistance testing can assist health care providers in deter-
mining ART regimens for patients that will have the highest
likelihood of success. Speciﬁcally, patients whose resistance
to nonnucleoside reverse transcriptase inhibitors (NNRTIs) is
detected before ﬁrst-line ART initiation can be assigned
a protease inhibitor (PI)–based regimen. Still, the Brazilian
national guidelines emphasize the need for additional studies
demonstrating the clear beneﬁt of this initial genotype
test strategy.
5
We hypothesized that the use of genotype-resistance
testing, at a cost of $230 per test,
10 before ART initiation in
ART-naive individuals within the scope of the Brazil
National Health System would be a cost-effective strategy
for the country. To examine this question, we used the Cost-
Effectiveness of Preventing AIDS Complications (CEPAC)-
International model to estimate the clinical impact,
economic costs, and cost-effectiveness of adding primary
genotype-resistance testing to the Brazilian Guidelines for
HIV treatment.
METHODS
Analytic Overview
We used the Cost-Effectiveness of Preventing AIDS
Complications (CEPAC)-International model, a previously
published microsimulation model of HIV disease,
11–13 to
project the clinical and economic outcomes of performing
a genotype test to detect NNRTI resistance before ﬁrst-line
ART initiation in Brazil. Resistance to NNRTI-based regi-
mens was chosen because it accounts for more than 3 quarters
of HIV primary drug resistance in Brazil and because
Brazilian national guidelines currently recommend an
NNRTI-based regimen as the preferred ﬁrst-line therapy.
5,14
We examined 2 strategies: (1) No genotype testing before
ﬁrst-line ART initiation (No genotype), an approximation of
the current standard of care in Brazil and (2) genotype testing
before ﬁrst-line ART initiation (Genotype). Both strategies
include genotype-resistance testing after ﬁrst-line failure, as
recommended in the Brazilian National Guidelines. Within
each strategy, we simulated both patients who did and did not
have NNRTI resistance and weighted the results based on the
prevalence of primary NNRTI resistance in Brazil (Fig. 1).
The outcomes of interest included per person life expectancy
and costs (both discounted at 3% per year), as well as the
incremental cost-effectiveness ratios and net health beneﬁtt o
provide comparative value of the Genotype strategy.
15 All
costs were reported in 2012 US dollars. Based on the
recommendations of the Commission on Macroeconomics
and Health,
16 we deﬁned a strategy to be “very cost-effective”
(or “cost-effective”) if its incremental cost-effectiveness ratio
was less than 1 time (or 3 times) the 2012 Brazilian per capita
GDP of US $12,300. Net health beneﬁt was calculated as the
difference in discounted effectiveness between the Genotype
strategy and the No genotype strategy, minus the quotient of
the difference in costs between the 2 strategies and the
willingness-to-pay threshold (measured in dollars per addi-
tional life-year saved) and assumed to be the annual per capita
GDP of Brazil.
17
The CEPAC-International Model
The CEPAC-International model is a microsimula-
tion of HIV disease progression and treatment. The model
simulates a distinct trajectory for each individual patient,
using a random number generator and known transition
probabilities to determine the occurrence of monthly
transitions between “health states.” The health states are
deﬁned to be both descriptive of the patient’s current
health (CD4 count, HIV RNA level, relevant history of
opportunistic infections (OIs) and treatment-related tox-
icities, and resource use) and predictive of future disease
progression (immune system deterioration, onset and
relapse of OIs, ART status, toxic reactions to medications,
resistance to therapy, and mortality). CD4 and HIV RNA
levels dictate the rate of CD4 count decline, and CD4
count determines the probabilities of OIs and AIDS-
related mortality. The model takes note of variability in
patient adherence to medication and uses that information
to estimate both initial and long-term virologic response to
treatment and loss to follow-up. Results of multiple
individual simulations are then aggregated to produce
stable estimates of survival and costs. A more complete
description of the model is provided in the Tech-
nical Appendix (see Supplemental Digital Content,
http://links.lww.com/QAI/A595) and in the CEPAC
Model User’s Guide.
18
At model entry, patients are assigned an adherence
value (0%–100%) according to a distribution derived from
a cohort of commercially insured HIV-infected patients in
the United States,
19 indicating their likelihood to adhere to
treatment. For each line of ART, patients are assigned an
initial probability of achieving virologic suppression at 24
weeks, after which they face a monthly probability of
virologic rebound and subsequent CD4 decline. Both the
probability of suppression and the subsequent monthly
probability of virologic rebound are dependent on a patient’s
adherence value. An initial genotype test is performed for all
patients at ART initiation in the Genotype strategy. After
failure on a regimen has been detected through standard
viral load monitoring, patients in both strategies incur the
cost and information of a genotype test before starting on the
next line of ART. After failing the last of 5 available
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monthly probabilities of going loss to follow-up and of
returning to care also are dependent on a patient’s
adherence value. We structure care in the model to
conform to Brazilian national guidelines for HIV treat-
ment. Speciﬁcally, patients begin antiretroviral therapy
when their CD4 count drops below the current Brazil
recommendation of ,500 per microliter.
5 CD4 count tests
are conducted every 3 months until patients are eligible for
ART. Once on ART, patients’ CD4 count and HIV RNA
levels are monitored every 3 months. Patients received
both prophylaxis and treatment for OIs in accordance with
Brazilian guidelines.
Input Parameters for the Analysis
Data on cohort characteristics, natural history, and
resource utilization were derived from the HIV Clinical
Cohort at the Evandro Chagas Clinical Research Institute
(IPEC) of the Oswaldo Cruz Foundation. IPEC is a public
health care institution situated in Rio de Janeiro, Brazil. It is
one of the Brazil’s largest reference centers for HIV
research and has provided care to over 5000 patients in
the urban HIV-infected population of Rio de Janeiro
Metropolitan area since 1986. A detailed description of
the cohort and the methods of data collection and parameter
estimation are in the Technical Appendix (see Supplemental
Digital Content, http://links.lww.com/QAI/A595).
Cohort Characteristics
The simulated cohort consisted of treatment-naive HIV-
infected adults, with age, sex, initial CD4 count, and HIV RNA
levels estimated from the cohort of 1819 individuals who
presented for HIV care at IPEC between 2000 and 2010
(Table 1). Sixty-nine percent were male, mean age was 36
years (SD, 10 years), and mean CD4 count at entry to care was
347 per microliter (SD, 300/mL). The prevalence of primary
NNRTI resistance of 4.4% was derived from a surveillance
study carried out in the 13 most populous Brazilian cities.
14
Natural History
Natural history parameters were obtained from a study
population that included adult patients (aged $18 years) who
enrolled in the IPEC cohort and had a minimum follow-up of
60 days from 1986 through 2010. Natural history parameters
included the incidence rate of OIs and mortality rates,
stratiﬁed by both CD4 count and ART use as described in
previous CEPAC Model publications.
33 Within each CD4
stratum, OI incidence and mortality rates were assumed to
remain constant for the time period evaluated and were
converted into monthly probabilities for model input.
ART Efﬁcacy and Loss to Follow-up
ART efﬁcacy and loss to follow-up inputs were stratiﬁed
by ART adherence levels. A logit adherence distribution was ﬁt
FIGURE 1. Decision tree diagram for a model of HIV genotype testing. Results of each of the 4 arms (No Resistance, No Genotype;
No Resistance, Genotype; Resistance, No Genotype; Resistance, Genotype) are weighted based on the prevalence of NNRTI resistance
in Brazil. Initial ART regimen and efﬁcacy vary by arm. Subsequent-line ART regimens are identical for each arm.
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Variable Base-Case Value Reference
Cohort characteristics
Age, mean (SD), yrs 36 (10)
Male sex, (%) 69
Initial CD4 count, mean cells/mL (SD) 347 (300)
HIV RNA distribution, (%)
.100,000 copies/mL 35
30,001–100,000 copies/mL 22
10,001–30,000 copies/mL 18
3001–10,000 copies/mL 12
501–3000 7
,500 copies/mL 6
Prevalence of NNRTI resistance (%) 4.4 14
Natural history CD4 count (cells/mL)
.500 350–500 200–350 100–200 50–100 0–50
Mean baseline CD4 decline by HIV RNA,
monthly (SD)
Calculated from Refs.
20–22
.30,000 copies/mL 9.5 (0.3) 7.9 (0.3) 6.3 (0.3) 4.7 (0.3) 3.3 (0.3) 1.4 (0.3)
10,001–30,000 copies/mL 6.8 (0.2) 5.7 (0.2) 4.6 (0.2) 3.3 (0.2) 2.4 (0.2) 1.0 (0.2)
3001–10,000 copies/mL 5.9 (0.2) 4.9 (0.2) 3.9 (0.2) 2.9 (0.2) 2.0 (0.2) 0.8 (0.2)
501–3000 4.8 (0.2) 4.0 (0.2) 3.2 (0.2) 2.3 (0.2) 1.6 (0.2) 0.7 (0.2)
,500 copies/mL 2.4 (0.3) 2.0 (0.3) 1.6 (0.3) 1.2 (0.3) 0.8 (0.3) 0.4 (0.3)
Chronic AIDS death probability, monthly
No OI History 0.00018 0.00126 0.00126 0.00279 0.00797 0.00817
OI History 0.00018 0.00126 0.03692 0.03692 0.05665 0.05665
OI probability, monthly
Combination OI (PCP, MAC, CMV) 0.00010 0.00014 0.00063 0.00338 0.00400 0.01724
Toxoplasmosis 0.00003 0.00026 0.00026 0.00135 0.00334 0.00496
Tuberculosis 0.00037 0.00092 0.00272 0.00941 0.00941 0.01317
Other OI 0.00124 0.00225 0.00301 0.00765 0.01197 0.02212
All CD4 strata
Death from OI probability, monthly
Combination OI (PCP, MAC, CMV) 0.13433
Toxoplasmosis 0.12500
Tuberculosis 0.05145
Other OI 0.06631
ART efﬁcacy and loss to follow-up
Adherence distribution 19
% with adherence .95% 45
% with adherence between 50 and 95% 54.5
% with adherence ,50% 0.5
HIV RNA suppression (%) and mean CD4
gain (cells/mL)
HIV RNA suppression* Mean CD4 gain†
First-line NNRTI regimen without NNRTI
resistance
85 197 23
First-line NNRTI regimen with NNRTI
resistance
63 197 23,34
First-line PI regimen with NNRTI resistance 81 197 24
Second-line PI regimen 80 197 25
Third-line INSTI-containing regimen 75 148 26
Fourth-line second generation NNRTI-
containing regimen
70 107 27,28
Fifth-line CCR5-containing regimen 60 141 29,30
Virologic failure rate after 6 months (/100 PY) Assumption
(continued on next page)
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19 We
assumed that 0.5% of the cohort had poor adherence to ART (ie,
,50% adherence), that 45% of the cohort had excellent
adherence to ART (ie, .95% adherence), and that the
remaining 54.5% fell between these 2 extremes. To determine
ART efﬁcacy, we assumed that patients who almost never take
their medication (ie, those whose adherence is below 5%) do not
achieve virologic suppression. We then calibrated the probabil-
ity of virologic suppression for excellent adherers (.95%),
interpolating linearly for all other adherence values, so that the
overall average suppression for the entire cohort matched data
from published literature for each regimen (Table 1). Patients
who were suppressed on a given regimen faced an adherence-
dependent monthly probability of virologic rebound. This risk
was calibrated so that fewer than 2% of patients reach the last
line of ART. Rates of loss to follow-up and return to care were
derived from data from the IPEC cohort and were calculated
to be 4.1 and 81.8 per 100 person-years, respectively
(see Technical Appendix, Supplemental Digital Content,
http://links.lww.com/QAI/A595).
No NNRTI Resistance, With and Without Genotype
In the model, patients who did not have NNRTI
resistance were eligible to receive up to 5 sequential lines
of ART. First-line therapy was an NNRTI-based regimen, and
second-line therapy was a PI-based regimen. Patients who
failed ﬁrst- and second-line therapy received subsequent lines
of ART that increased in regimen complexity and cost and
decreased in rates of suppression (Table 1).
NNRTI Resistance Without Genotype
Patients who had NNRTI resistance but did not receive
a genotype test received the same sequence of ART regimens
as patients who did not have NNRTI resistance; however,
their ability to successfully respond to the ﬁrst NNRTI-based
regimen was decreased. We lowered the virologic suppres-
sion rate at 24 weeks for the NNRTI regimen by applying
a calculated relative risk of failure of 2.6,
34 decreasing the
overall average suppression from 85% to 63%. We assumed
that all patients with NNRTI resistance who become sup-
pressed at 24 weeks, regardless of their adherence level, face
TABLE 1. (Continued) Base-Case Inputs for a Model of HIV Genotype-Resistance Testing in Brazil
Variable Base-Case Value Reference
All regimens, except NNRTI with NNRTI
resistance
Adherence .95% 0.3
Adherence ,50% 16.2
Overall average for ﬁrst-line regimen§ 1.5
NNRTI with NNRTI resistance
All adherence levels 16.2
Loss to follow-up (/100 PY)
Rate of loss to follow-up, overall average 4.1
Rate of return to care, overall average 81.8
Costs (2012 US $)
Routine care costs, annual 60–660k 31,32
Test costs, per test 10
CD4 20
HIV RNA 23
Genotype 230
Antiretroviral therapy, annual 10
NNRTI regimen 1400
PI regimen as ﬁrst-line ART 2200
PI regimen as second-line ART 1800
INSTI regimen 12,800
Second generation NNRTI regimen 13,400
CCR5 regimen 6700
Acute OI event 300–700 31,32
Mortality cost 1,100
*Assuming that patients who take ,5% of their medication cannot achieve virologic suppression (ie, 0% suppression), we calibrated the probability of virologic suppression for
patients who take .95% of their medication (a model input), so that the overall average suppression for all patients at 6 months matched data from published literature.
†Mean CD4 gain is reported at 12 months for suppressed patients and was calculated from 48- or 96-week immunologic data from published literature. CD4 gain for suppressed
patients was assumed to be equal for ﬁrst- and second-line regimens (Personal communication with Beatriz Grinsztejn and Paul Sax).
‡Virologic failure rates were calibrated to reﬂect a reasonable distribution of time spent on each line of ART according to expert clinician consultation.
§Although the model inputs for the virologic failure rate after 6 months for patients who take ,50% of their medication and .95% of their medication remain the same for each
line of ART, the overall average virologic failure rate will differ by regimen, as it is dependent on the distribution and characteristics of the patients starting on each line of ART (eg,
adherence levels, proportion of patients starting on each line of ART, etc.).
kRoutine annual care costs were stratiﬁed by CD4 stratum, where patients with higher CD4 counts accrued fewer costs than those with lower CD4 counts.
CCR5, C–C chemokine receptor type 5; CMV, cytomegalovirus; INSTI, integrase inhibitor; MAC, mycobacterium avium complex; PCP, Pneumocystis jirovecii pneumonia; PY,
person-years.
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person-years—equivalent to the rate of late failure after 24
weeks for poorly adherent patients without NNRTI resistance.
NNRTI Resistance With Genotype
Patients who had NNRTI resistance and received
a genotype test received a PI-based regimen as their ﬁrst-line
ART, instead of an NNRTI-based regimen. After ﬁrst-line
failure, these patients began the same PI-based regimen that all
patients received as second-line ART. Thereafter, these patients
received the same third- through ﬁfth-line ART as those
without NNRTI resistance, with the same probability of
suppression as nonresistant patients.
Costs
We conducted the economic analysis from the perspec-
tive of the public National Health System and, therefore,
restricted our attention to direct HIV-related medical costs.
All unit costs were obtained either from the Brazilian
Ministry of Health or from the administrative department of
IPEC and converted from Brazilian reais to 2012 US dollars
using a GDP deﬂator and the average exchange rate for
2012.
35 Costs for routine care and acute OI events were
calculated by multiplying the unit costs for inpatient and
outpatient visits by the number of inpatient and outpatient
days associated with routine chronic care (stratiﬁed by CD4
count), acute events, and death, reported between 2005 and
2010 for the HIV Clinical Cohort at IPEC (see Technical
Appendix, Supplemental Digital Content, http://links.lww.
com/QAI/A595). The annual cost of the individual lines of
ART ranged from $1400 to $13,400 (Table 1), and the cost of
the genotype test was $230.
10
Sensitivity Analyses
To understand the impact of data uncertainty on our
ﬁndings, we conducted univariate and multivariate sensitivity
analyses. Ranges explored for each parameter were derived
from the literature (eg, NNRTI resistance prevalence) or
deﬁned based on plausible ranges (eg, NNRTI regimen
efﬁcacy in patients who had NNRTI resistance but did not
receive a genotype test, genotype test cost, and subsequent-
line ART costs). Multivariate sensitivity analyses were
conducted on 3 of the most inﬂuential parameters to
demonstrate their interactions.
RESULTS
Base Case
Among patients without NNRTI resistance, genotyping
had no impact on discounted life expectancy (221.6 months) but
slightly increased projected per-person lifetime costs from
$43,980 to $44,290 (Table 2). For patients with NNRTI
resistance, however, genotyping produced a substantial
improvement in life expectancy (from 217.7 to 221.2 months)
and a reduction in costs (from $67,200 to $55,130). These
reduced costs are a result of fewer complications associated with
viral load rebound and with a smaller proportion of time spent
on more expensive third through ﬁfth lines of ART. When
weighting these results based on the prevalence of NNRTI
resistance in Brazil (4.4%), the current standard of care in Brazil
yielded a discounted life expectancy of 221.4 months (18.45
years) and a discounted lifetime cost of US $45,000. The use of
genotype-resistance testing before ART initiation yielded a high-
er discounted life expectancy of 221.6 months (18.47 years) and
a lower discounted lifetime cost of US $44,770. Therefore, the
Genotype strategy was cost saving compared with No Genotype,
because it costs less and yielded greater life expectancy.
Genotype had a positive net health beneﬁt of 0.035 discounted
years of life saved (YLS); that is, it rendered a gain in net health
beneﬁt when compared with the No Genotype strategy.
Univariate Sensitivity Analysis
In univariate sensitivity analyses, we varied major input
parameters independently within their plausible ranges. One-
TABLE 2. Base-Case Results for an Analysis of HIV Genotype Testing in Brazil
Discounted Cost
(2012 US $)
Undiscounted
LE (months)
Discounted
LE (months)
NHB*
(YLS)
ICER†
($/YLS)
Cohort-based outcomes
No NNRTI resistance No genotype 43,980 389.4 221.6 ——
No NNRTI resistance Genotype 44,290 389.4 221.6 ——
NNRTI resistance No genotype 67,200 381.1 217.7 ——
NNRTI resistance Genotype 55,130 388.5 221.2 ——
Population-wide outcomes, weighted by the
prevalence of resistance (4.4%)
No genotype 45,000 389.0 221.4 ——
Genotype 44,770 389.4 221.6 0.035 Cost saving
*Gain in net health beneﬁt (NHB) rendered with a given strategy as compared with that rendered with the reference strategy was calculated as the difference in discounted
effectiveness between the Genotype strategy and the No Genotype strategy, minus the quotient of the difference in discounted cost between the Genotype strategy and the No Genotype
strategy and the willingness-to-pay threshold, here assumed to be 1 time the per capita Gross Domestic Product of the Brazil (2012 per capita GDP = $12,300).
†ICER, reported in 2012 US $ per life-year saved, was calculated as the incremental difference in cost divided by the incremental difference in life-years. By convention, a strategy
that costs less and yields greater life savings compared with the reference strategy is labeled cost saving and no ICER is reported.
ICER, incremental cost-effectiveness ratio; LE, life expectancy; NHB, net health beneﬁt.
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across all plausible parameter ranges (Fig. 2). They also
identiﬁed inﬂuential parameters that could produce noteworthy
changes in net health beneﬁt ﬁndings. The most inﬂuential
parameter was NNRTI resistance prevalence which, when
varied from 2% to 7%, yielded net health beneﬁtv a l u e s
ranging from 0.003 to 0.070 YLS. As the efﬁcacy of ﬁrst-line
NNRTI-based ART in resistant patients not receiving genotype
testing increased, thus reducing the detrimental effect of
NNRTI resistance, overall net health beneﬁto fGenotype
decreased. Reducing subsequent-line ART costs by 60%
decreased the net health beneﬁto ft h eGenotype strategy from
the base-case value of 0.035 to 0.002 YLS. Other parameter
variations that caused an appreciable decrease in net health
beneﬁt were increasing the genotype test cost and decreasing
the probability of virologic failure after suppression for
resistant patients not receiving a genotype test.
Multivariate Sensitivity Analysis
Figure 3 depicts the behavior of the cost-effectiveness
ﬁndings as we varied 3 of the more inﬂuential parameters
identiﬁed in the 1-way sensitivity analyses: the cost of the
genotype test (increased and decreased 50% from baseline
value); the cost of subsequent ART regimens (from 100% to
10% baseline value); and the prevalence of NNRTI primary
resistance (from 0.1% to 5.0%). In the base-case scenario
(depicted by the black dot in the central panel), we observed
cost savings. Genotype was cost saving, for example, even
when both subsequent-line ART costs decreased to 80% of
baseline values and resistance prevalence decreased to 3.7%.
If the cost of the genotype test was reduced by 50% (right
panel), cost savings were achieved in a wider range of
scenarios, including at resistance prevalence as low as 1.3%.
Even when the genotype test cost was increased to 150% of
baseline value (left panel), initial genotype remained a cost-
effective strategy over a broad range of plausible parameter
changes, such as reducing the cost of subsequent ART to
60% of baseline value while resistance prevalence decreased
to 3.4%.
DISCUSSION
Since 1996, the Brazilian government has guaranteed
universal provision of ART, free of charge, to HIV–infected
individuals.
4 ART guidelines for the country are set forth by
the Department of Sexually Transmitted Diseases, AIDS, and
Viral Hepatitis within the Ministry of Health. Although the
FIGURE 2. Univariate sensitivity analysis tornado plot of selected parameters. The diagram summarizes the results of a series of
1-way sensitivity analyses on the net health beneﬁt of genotyping. Each horizontal bar represents the range of net health beneﬁt
produced by varying a given model parameter across the parameter ranges in parentheses. Net health beneﬁt is deﬁned as the
YLS minus the quotient of the difference in cost between the 2 strategies and the annual willingness-to-pay threshold (here, the
2012 annual per capita GDP of Brazil US $12,300). The vertical line represents the base-case net health beneﬁt for the Genotype
strategy. NHB, net health beneﬁt; LE, life expectancy.
NHB ¼

LEGenotype 2LENo Genotype

2

CostGenotype 2CostNo Genotype
Willingness  to  pay  threshold

:
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type testing after failure of ﬁrst-line ART, they do not
recommend routine use of genotype testing before initiating
ﬁrst-line ART, citing a lack of evidence for the clear beneﬁts
of this strategy.
Genotype-resistance testing can help identify more
effective antiretroviral regimens for patients, thus substantially
increasing the likelihood of viral suppression and immune
recovery.
36 We used the most recent surveillance study of
primary resistance conducted in 20 centers from 13 highly
populous cities in Brazil
14 and data from a large Brazilian
clinical cohort to derive inputs for a simulation model for the
present analysis. We found that genotype-resistance testing
was cost saving at resistance prevalence as low as 2.6%, much
lower than the reported value of 4.4%.
Although primary resistance prevalence was the most
inﬂuential factor on the cost-effectiveness of initial genotype-
resistance testing, subsequent-line ART costs were also an
important factor. This is because, without a genotype test,
resistant patients are likely to fail their initial regimen,
experience poorer clinical outcomes, and spend an increased
proportion of their lives on more expensive and less tolerable
subsequent-line regimens. Over time, it is likely that these
expensive regimen costs will decrease, making initial
genotype-resistance testing less attractive. However, our
results suggest that Genotype will remain cost-effective unless
subsequent-line ART costs fall below 30% of their current
value. Given that the Genotype strategy is projected to
decrease per-patient lifetime costs by US $230 (Table 2),
for an estimated 45,000 patients initiating ART in Brazil each
year,
10 and with stable costs over time, the Genotype strategy
could yield a projected annual cost savings of US $10.4
million.
The results of this analysis should be interpreted in light
of certain limitations in model parameters and assumptions.
First, in the base case, we assumed that the prevalence of
primary NNRTI resistance, a key parameter of this analysis,
was similar across the country. Though this is certainly not the
case, the HIV epidemic is mostly concentrated in large urban
centers, and these were appropriately chosen for the nation-
wide primary resistance prevalence study that was used to
derive model inputs. Nonetheless, we conducted univariate and
multivariate sensitivity analyses to evaluate the impact of
plausible variation in NNRTI resistance prevalence. These
analyses showed that, for most of the explored prevalence, the
Genotype strategy either remained cost saving or reached cost-
effective results. Second, although our standard-of-care strat-
egy assumed that no one starting treatment would be offered
a genotype test, the most recent guidelines published in 2013
state that pregnant women and individuals infected by an HIV-
infected partner on ART could make use of the test. It is
possible that, if we included these exceptions to the current
Genotype strategy, the strategy would become less appealing.
However, such changes would not alter our conclusions
substantially because these populations represent only a small
fraction of those starting ART in Brazil.
37–39 Third, to obtain
input data estimates for the model, we used data from the HIV-
infected Cohort at IPEC and other published ofﬁcial Brazilian
government sources. We used sensitivity analysis to evaluate
which of these parameters inﬂuenced our ﬁndings most
strongly and how our conclusions would be affected by the
variation in the parameter values; we found that our conclusions
were robust. Fourth, when modeling the Genotype strategy, we
assumed it was completely implemented; inadequate imple-
mentation would yield both life expectancy and cost for the
genotype strategy that are lower, though the cost-effectiveness
FIGURE 3. Multivariate sensitivity analysis color plot. Parameters varied simultaneously were genotype test cost, subsequent-line
ART costs, and primary NNRTI resistance prevalence. Colors are arranged from green (cost saving) to red (not cost-effective). The
black dot in the middle panel indicates the base-case result. ICER: Incremental cost-effectiveness ratio; not cost-effective: ICER
.3 times the 2012 annual per capita GDP of Brazil of 2012 (ICER .$36,900); cost-effective: 1 time , ICER ,3times the 2012
annual per capita GDP of Brazil ($12,300 , ICER , $36,900); very cost-effective: ICER $0 , ICER , 1 time the 2012 annual per
capita GDP of Brazil ($0 , ICER , $12,300); cost saving: ICER ,$0.
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the health beneﬁts that accrue to the individual and the
economic implications for the health system but does not
address potential population-level effects of primary resistance
testing. Such population beneﬁts might include decreased
transmission of resistant virus to HIV-uninfected individuals,
w h i c hw o u l dm a k et h eGenotype strategy even more appealing.
Previous economic analyses have shown the cost-
effectiveness of initial genotype-resistance testing before
initiating ﬁrst-line ART therapy in the United States.
9 Here,
we present the ﬁrst analysis to show the potential cost savings
of this initial genotype strategy in a middle-income country. In
Brazil, similar to antiretroviral drugs and other laboratory tests,
genotype-resistance testing is provided by the federal govern-
ment, free of charge, to patients in 24 reference centers
throughout the country. Although obstacles were experienced
during its implementation in 2001, the procedures required for
performing the test are currently well established. Furthermore,
the interpretation of the test result is carried out by a designated
group of experts and follows a standardized procedure that
includes evaluating the results in light of each patient’sA R T
history and recommending a new ART regimen. By identify-
ing individuals with primary resistance, genotype-resistance
testing, with its 1-time cost, provides an opportunity for the
health care provider to allocate patients to a regimen with
a high likelihood of success and for the government to reduce
overall costs of HIV care. We ﬁnd that initial genotype-
resistance testing will improve survival and decrease costs and
should be incorporated into both HIV treatment guidelines and
the standards of care in Brazil.
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